| RS2514538137 |
JAG1
|
Health Risk |
Likely pathogenic |
Alagille syndrome due to a JAG1 point mutation, Arteriohepatic dysplasia |
| RS2514538159 |
JAG1
|
Health Risk |
Pathogenic |
Alagille syndrome due to a JAG1 point mutation, Alagille syndrome due to a JAG1 point mutation |
| RS2514538551 |
SLC4A11
|
Health Risk |
Pathogenic |
— |
| RS2514538931 |
JAG1
|
Health Risk |
Pathogenic |
Alagille syndrome due to a JAG1 point mutation, Alagille syndrome due to a JAG1 point mutation |
| RS2514538986 |
JAG1
|
Health Risk |
Likely pathogenic |
Alagille syndrome due to a JAG1 point mutation, Arteriohepatic dysplasia |
| RS2514539387 |
SLC4A11
|
Health Risk |
Pathogenic |
— |
| RS2514541181 |
RYR1
|
Health Risk |
Likely pathogenic |
RYR1-related disorder, RYR1-related disorder |
| RS2514544261 |
JAK3
|
Health Risk |
Pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514544299 |
JAK3
|
Health Risk |
Likely pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514544388 |
JAK3
|
Health Risk |
Pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514545916 |
RBCK1
|
Health Risk |
Likely pathogenic |
Polyglucosan body myopathy type 1, Polyglucosan body myopathy type 1 |
| RS2514545949 |
RBCK1
|
Health Risk |
Pathogenic |
Polyglucosan body myopathy type 1, Polyglucosan body myopathy type 1 |
| RS2514546031 |
JAK3
|
Health Risk |
Likely pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514546551 |
JAK3
|
Health Risk |
Likely pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514549046 |
JAK3
|
Health Risk |
Likely pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514549413 |
JAK3
|
Health Risk |
Likely pathogenic |
— |
| RS2514549645 |
JAK3
|
Health Risk |
Pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514549730 |
JAK3
|
Health Risk |
Pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514550384 |
JAK3
|
Health Risk |
Pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514550586 |
SLC4A11
|
Health Risk |
Likely pathogenic |
— |
| RS2514551572 |
SLC4A11
|
Health Risk |
Pathogenic |
— |
| RS2514553135 |
JAK3
|
Health Risk |
Pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514553390 |
JAK3
|
Health Risk |
Pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514554819 |
JAK3
|
Health Risk |
Pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514555104 |
SLC4A11
|
Health Risk |
Pathogenic |
— |
| RS2514556610 |
JAK3
|
Health Risk |
Pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514556659 |
JAK3
|
Health Risk |
Pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514558988 |
SLC4A11
|
Health Risk |
Pathogenic |
— |
| RS2514559502 |
JAK3
|
Health Risk |
Likely pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514559505 |
JAK3
|
Health Risk |
Pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514560054 |
SLC4A11
|
Health Risk |
Pathogenic |
— |
| RS2514560903 |
SMARCA4
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Rhabdoid tumor predisposition syndrome 2 |
| RS2514561147 |
SLC4A11
|
Health Risk |
Likely pathogenic |
— |
| RS2514561322 |
JAK3
|
Health Risk |
Pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514563055 |
SLC4A11
|
Health Risk |
Likely pathogenic |
— |
| RS2514565960 |
SMARCA4
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2514566418 |
JAK3
|
Health Risk |
Likely pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514566459 |
JAK3
|
Health Risk |
Pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514568357 |
JAK3
|
Health Risk |
Pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514569208 |
SLC4A11
|
Health Risk |
Pathogenic |
— |
| RS2514570481 |
SLC4A11
|
Health Risk |
Likely pathogenic |
Corneal dystrophy, Fuchs endothelial |
| RS2514570944 |
JAK3
|
Health Risk |
Likely pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514571932 |
JAK3
|
Health Risk |
Pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514572030 |
JAK3
|
Health Risk |
Pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514572175 |
JAK3
|
Health Risk |
Pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514574248 |
RYR1
|
Health Risk |
Conflicting classifications of pathogenicity |
RYR1-related disorder, Malignant hyperthermia |
| RS2514575421 |
RYR1
|
Health Risk |
Pathogenic |
RYR1-related disorder, RYR1-related disorder |
| RS2514575779 |
JAK3
|
Health Risk |
Pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514576148 |
JAK3
|
Health Risk |
Pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514577444 |
RYR1
|
Health Risk |
Pathogenic |
RYR1-related disorder, RYR1-related disorder |
| RS2514577605 |
RYR1
|
Health Risk |
Pathogenic |
RYR1-related disorder, RYR1-related disorder |
| RS2514577804 |
JAK3
|
Health Risk |
Pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514578433 |
JAK3
|
Health Risk |
Likely pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514578977 |
RYR1
|
Health Risk |
Conflicting classifications of pathogenicity |
RYR1-related disorder, Malignant hyperthermia |
| RS2514579231 |
JAK3
|
Health Risk |
Likely pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514579287 |
RYR1
|
Health Risk |
Conflicting classifications of pathogenicity |
RYR1-related disorder, Malignant hyperthermia |
| RS2514579552 |
RYR1
|
Health Risk |
Pathogenic |
RYR1-related disorder, RYR1-related disorder |
| RS2514580420 |
JAK3
|
Health Risk |
Likely pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, Thyroid cancer |
| RS2514582034 |
JAK3
|
Health Risk |
Likely pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514582221 |
JAK3
|
Health Risk |
Pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514582341 |
JAK3
|
Health Risk |
Pathogenic |
T-B+ severe combined immunodeficiency due to JAK3 deficiency, T-B+ severe combined immunodeficiency due to JAK3 deficiency |
| RS2514591958 |
RYR1
|
Health Risk |
Likely pathogenic |
— |
| RS2514592098 |
SLC4A11
|
Health Risk |
Pathogenic |
— |
| RS2514599740 |
SLC4A11
|
Health Risk |
Pathogenic |
— |
| RS2514599811 |
RYR1
|
Health Risk |
Likely pathogenic |
RYR1-related disorder, King Denborough syndrome |
| RS2514600162 |
RYR1
|
Health Risk |
Likely pathogenic |
RYR1-related disorder, RYR1-related disorder |
| RS2514600175 |
RYR1
|
Health Risk |
Likely pathogenic |
RYR1-related disorder, RYR1-related disorder |
| RS2514600630 |
RYR1
|
Health Risk |
Conflicting classifications of pathogenicity |
Malignant hyperthermia, susceptibility to |
| RS2514601212 |
RYR1
|
Health Risk |
Pathogenic |
RYR1-related disorder, RYR1-related disorder |
| RS2514601734 |
SLC4A11
|
Health Risk |
Pathogenic |
— |
| RS2514607038 |
SLC4A11
|
Health Risk |
Pathogenic |
— |
| RS2514611070 |
SLC5A5
|
Health Risk |
Pathogenic |
— |
| RS2514611636 |
SLC5A5
|
Health Risk |
Pathogenic |
— |
| RS2514611674 |
SLC5A5
|
Health Risk |
Pathogenic/Likely pathogenic |
SLC5A5-related disorder, Thyroid dyshormonogenesis 1 |
| RS2514612011 |
SLC5A5
|
Health Risk |
Pathogenic |
— |
| RS2514615050 |
SLC5A5
|
Health Risk |
Likely pathogenic |
— |
| RS2514620296 |
SLC5A5
|
Health Risk |
Pathogenic |
— |
| RS2514623680 |
SLC5A5
|
Health Risk |
Pathogenic |
— |
| RS2514624226 |
SLC5A5
|
Health Risk |
Likely pathogenic |
— |
| RS2514624625 |
SLC5A5
|
Health Risk |
Likely pathogenic |
— |
| RS2514625219 |
SLC5A5
|
Health Risk |
Likely pathogenic |
— |
| RS2514631082 |
PNKP
|
Health Risk |
Pathogenic |
Developmental and epileptic encephalopathy, 12 |
| RS2514631912 |
PNKP
|
Health Risk |
Pathogenic |
Developmental and epileptic encephalopathy, 12 |
| RS2514632975 |
CSNK2A1
|
Health Risk |
Likely pathogenic |
— |
| RS2514633332 |
PNKP
|
Health Risk |
Pathogenic |
— |
| RS2514633587 |
PNKP
|
Health Risk |
Pathogenic |
Microcephaly, seizures |
| RS2514634940 |
SLC4A11
|
Health Risk |
Pathogenic |
— |
| RS2514635320 |
SLC4A11
|
Health Risk |
Pathogenic |
— |
| RS2514636093 |
PNKP
|
Health Risk |
Pathogenic |
Developmental and epileptic encephalopathy, 12 |
| RS2514636796 |
SLC5A5
|
Health Risk |
Likely pathogenic |
— |
| RS2514637165 |
PNKP
|
Health Risk |
Likely pathogenic |
Microcephaly, seizures |
| RS2514637650 |
SLC5A5
|
Health Risk |
Pathogenic |
— |
| RS2514637765 |
SLC5A5
|
Health Risk |
Pathogenic |
— |
| RS2514637870 |
SMARCA4
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2514638711 |
PNKP
|
Health Risk |
Pathogenic |
Developmental and epileptic encephalopathy, 12 |
| RS2514640200 |
DLL3
|
Health Risk |
Pathogenic |
— |
| RS2514641142 |
CSNK2A1
|
Health Risk |
Likely pathogenic |
Okur-Chung neurodevelopmental syndrome, Okur-Chung neurodevelopmental syndrome |
| RS2514643690 |
DLL3
|
Health Risk |
Likely pathogenic |
Spondylocostal dysostosis 1, autosomal recessive |
| RS2514643983 |
DLL3
|
Health Risk |
Pathogenic |
— |
| RS2514644062 |
PNKP
|
Health Risk |
Likely pathogenic |
Microcephaly, seizures |